Value Investing

Value Investing Articles

Sometimes mergers offer great scale. Sometimes they offer great opportunities for streamlining and much lower cost rationale for a combined entity. Other times they are just smoke and mirrors or an...
Any time that investors see a stock down 6% or more, they probably aren’t going to be too keen on hearing that the drop is actually supposed to be good news. If that big drop is from a securities...
Does it matter that these stocks are all valued with what might be nose-bleed valuations? Does it matter that these are almost all trading above the consensus analyst price targets?
24/7 Wall St. wanted to identify the companies from which we expect solid dividend news in the fourth quarter. We see at least these eight companies, mostly blue chip, announcing dividend hikes in...
The technology sector has been hot in 2016, and some of the stocks have such strong charts that their fundamentals may not even matter to technicians.
What most investors are looking for is a solid solution in what is a confusing market. So we have compiled a list of a few biotech companies that fit the bill, and analysts are saying they can fill...
It is not that often that one company gets two huge thumbs-up from analysts in the same week when there is not an earnings report. That is the case for Walgreens Boots Alliance.
The new reality seems to be that oil prices and the prices of metals have reached a level where analysts are again comfortable making key projections for upside.
In the week of August 27, there were seven key analyst calls for stocks to buy that were trading under $10 per share.
Merrill Lynch has reiterated its Buy rating and price objective on Salesforce.com, calling it the firm's favorite large cap growth idea for 2016.
Mylan is under fire for price gouging on its EpiPen. There has been some concern that this was a serious mistake by CEO Heather Bresch.
It almost seems too good to be true, but Caterpillar is still the best performing of the 30 Dow Jones Industrial Average components so far in 2016.
Credit Suisse has run bullish and bearish scenarios for what the firm feels is a reasonable upside and downside for each of its large cap pharmaceutical stocks.
24/7 Wall St. tracks dozens of analyst calls each day of the week. It turns out that there are still some gold stocks in which analysts see value and are telling their clients to buy the shares.
The quest for upside and value often leads to stocks with low market caps or stocks with low share prices — frequently stocks that are trading under $10.